Circulating BAFF levels were increased in SSc patients (Matsushita et al., 2007) and BAFF blockade modulated scleroderma phenotype in a bleomycin-mediated mouse model (Matsushita et al., 2018). Here, TNFSF13B is linked to systemic sclerosis.